WO2026038132 - USE OF GPR119 AGONISTS FOR THE TREATMENT OF WEIGHT RELATED DISORDERS
National phase entry is expected:
Publication Number
WO/2026/038132
Publication Date
19.02.2026
International Application No.
PCT/IB2025/058172
International Filing Date
12.08.2025
Title **
[English]
USE OF GPR119 AGONISTS FOR THE TREATMENT OF WEIGHT RELATED DISORDERS
[French]
UTILISATION D'AGONISTES DE GPR119 POUR LE TRAITEMENT DE TROUBLES LIÉS AU POIDS
Applicants **
MANKIND PHARMA LTD.
Inventors
RAI, Santosh Kumar
PATIL, Rakesh Ishwar
KUMAR, Rakesh
KUMAR, Anil
Priority Data
202411061030
12.08.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2198 | |
| EPO | Filing, Examination, Granting | 11192 | |
| Japan | Filing, Examination, Granting | 2340 | |
| South Korea | Filing, Examination, Granting | 2449 | |
| USA | Filing, Examination, Granting | 7340 |
Total:
25,519
Contact Us
Abstract[English]
The present invention relates to the use of GPR119 agonists for the treatment and/or prevention of weight related diseases and disorders such as obesity and corpulence.[French]
La présente invention concerne l'utilisation d'agonistes de GPR119 pour le traitement et/ou la prévention de maladies et de troubles liés au poids tels que l'obésité et la corpulence.